Drug Type Contrast agent, Small molecule drug |
Synonyms PMI 04, PMI04 |
Target- |
Mechanism Magnetic resonance imaging enhancers, PET imaging(Positron-emission tomography enhancers) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 1 | KR | D&D Pharmatech Co., Ltd.Startup | 30 Jan 2022 |
Amyotrophic Lateral Sclerosis | Phase 1 | KR | D&D Pharmatech Co., Ltd.Startup | 30 Jan 2022 |
Depressive Disorder | Phase 1 | KR | D&D Pharmatech Co., Ltd.Startup | 30 Jan 2022 |
Parkinson Disease | Phase 1 | KR | D&D Pharmatech Co., Ltd.Startup | 30 Jan 2022 |
Neurodegenerative Diseases | Phase 1 | US | 07 Aug 2019 | |
Inflammation | Phase 1 | US | 30 Jul 2019 | |
Nerve Degeneration | Phase 1 | - | - |